MENU

Supply Chain Intelligence about:

Sanofi Aventis

Company profile   United States

See Sanofi Aventis's products and suppliers

Thousands of companies like you use Panjiva to research suppliers and competitors.

Easy access to trade data

4,110 US import shipments
US

U.S. Customs records organized by company

4,110 U.S. shipments available for Sanofi Aventis, updated weekly since 2007
Date Supplier Customer Details 43 more fields
2023-05-07 Sanofi Aventis Deutschland GmbH
Sanofi Aventis
XXXXXXXXXXXXXXX
Bill of lading
2023-04-16 Sanofi Aventis Deutschland GmbH
Sanofi Aventis
XXXXXXXXXXXXXXX
Bill of lading
2023-04-12 Sanofi Aventis Deutschland GmbH
Sanofi Aventis
XXXXXXXXXXXXXXX XXXXXXXXXXXXXXX
Bill of lading
Shipment data shows what products a company is trading and more. Learn more

Explore trading relationships hidden in supply chain data

Contact information for Sanofi Aventis

 
Address
JOHN SMITH 126 VALLEY RD MONTCLAIR NJ 07042 US
 
 

Sample Bill of Lading

4,113 shipment records available

Date
2023-05-07
Shipper Name
Sanofi Aventis Deutschland Gmbh
Shipper Address
Building F821, Industrial Estate Hoechst, Frankfurt, Germany, 65926
Consignee Name
Sanofi Aventis Us Llc
Consignee Address
2500 SOUTHPOINT DRIVE FOREST PARK GA 30297 US
Weight
14325
Weight Unit
KG
Weight in KG
14325.0
Quantity
40
Quantity Unit
PKG
Measure Unit
CM
Shipment Origin
Germany
Details
14,325.0 kg
From port: Antwerp, Belgium
To port: The Port of Charleston, Charleston, South Carolina
Place of Receipt
Antwerpen
Foreign Port of Lading
Antwerp, Belgium
U.S. Port of Unlading
The Port of Charleston, Charleston, South Carolina
U.S. Destination Port
The Port of Charleston, Charleston, South Carolina
Commodity
XXXXXXXXXXXXXXX
Container
TTNU8743757
Marks Description
XXXXXXXX
Carrier Name
DANMAR LINES LTD
Vessel Name
POTOMAC EXPRESS
Voyage Number
018W
Bill of Lading Number
DMALBREA101551
Master Bill of Lading Number
ONEYHAMD06634500
Lloyd's Code
9349526
HTS Codes
HTS 3004.90

Recent Panjiva Research about Sanofi Aventis

20161202-insulin-us

Novo and Lilly Face Tough Growth in Diabetes, Trade Data Shows

The global prevalence of diabetes is growing, but can be a tough sector for pharmaceutical companies to make money in as recent results from Novo Nordisk and Eli Lilly demonstrate. Panjiva data shows that U.S. imports of insulin and related equipment fell 15% in the third quarter in dollar ter... Read more →